$TNXP
Tonix Pharmaceuticals Holding Corp.

2022 Q4 Form 10-Q Financial Statement

#000138713122011157 Filed on November 07, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $8.054M $7.390M $5.453M
YoY Change 12.13% 35.52% 70.94%
% of Gross Profit
Research & Development $24.67M $22.20M $13.08M
YoY Change 10.67% 69.71% 48.49%
% of Gross Profit
Depreciation & Amortization $836.0K $252.0K $10.00K
YoY Change 2996.3% 2420.0% 0.0%
% of Gross Profit
Operating Expenses $32.73M $22.20M $18.54M
YoY Change 11.02% 19.78% 54.46%
Operating Profit -$29.59M -$18.54M
YoY Change 59.65%
Interest Expense $1.048M $610.0K $7.000K
YoY Change -1516.22% 8614.29% -30.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$31.68M -$28.98M -$18.53M
YoY Change 7.2% 56.42% 54.53%
Income Tax
% Of Pretax Income
Net Earnings -$34.08M -$28.98M -$18.53M
YoY Change 15.33% 56.42% 54.53%
Net Earnings / Revenue
Basic Earnings Per Share -$0.69 -$1.60
Diluted Earnings Per Share -$0.55 -$0.69 -$1.618M
COMMON SHARES
Basic Shares Outstanding 57.54M shares 43.06M shares 11.58M shares
Diluted Shares Outstanding 41.94M shares 11.58M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $120.2M $140.0M $183.0M
YoY Change -32.71% -23.5% 228.49%
Cash & Equivalents $120.2M $140.0M $183.0M
Short-Term Investments
Other Short-Term Assets $10.55M $11.16M $12.11M
YoY Change 1.53% -7.85% 89.25%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $130.8M $151.1M $195.1M
YoY Change -30.82% -22.53% 214.65%
LONG-TERM ASSETS
Property, Plant & Equipment $93.81M $90.31M $19.30M
YoY Change 85.56% 367.89% 271.17%
Goodwill
YoY Change
Intangibles $120.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets $384.0K $360.0K $271.0K
YoY Change 1.32% 32.84% 35.5%
Total Long-Term Assets $94.91M $91.51M $19.69M
YoY Change 83.05% 364.69% 251.64%
TOTAL ASSETS
Total Short-Term Assets $130.8M $151.1M $195.1M
Total Long-Term Assets $94.91M $91.51M $19.69M
Total Assets $225.7M $242.6M $214.8M
YoY Change -6.31% 12.98% 217.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.068M $4.556M $7.964M
YoY Change -39.26% -42.79% 342.44%
Accrued Expenses $10.11M $8.784M $4.062M
YoY Change 19.9% 116.25% 56.23%
Deferred Revenue $3.273M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.18M $13.34M $12.03M
YoY Change -16.28% 10.93% 173.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $328.0K $382.0K $530.0K
YoY Change -29.76% -27.92% -24.29%
Total Long-Term Liabilities $328.0K $382.0K $530.0K
YoY Change -29.76% -27.92% -24.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.18M $13.34M $12.03M
Total Long-Term Liabilities $328.0K $382.0K $530.0K
Total Liabilities $18.51M $13.72M $12.56M
YoY Change -16.57% 9.29% 151.12%
SHAREHOLDERS EQUITY
Retained Earnings -$470.0M -$438.4M -$330.3M
YoY Change 30.63% 32.73%
Common Stock $677.4M $667.4M
YoY Change 17.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $207.2M $228.9M $202.2M
YoY Change
Total Liabilities & Shareholders Equity $225.7M $242.6M $214.8M
YoY Change -6.31% 12.98% 217.71%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$34.08M -$28.98M -$18.53M
YoY Change 15.33% 56.42% 54.53%
Depreciation, Depletion And Amortization $836.0K $252.0K $10.00K
YoY Change 2996.3% 2420.0% 0.0%
Cash From Operating Activities -$22.30M -$23.53M -$12.95M
YoY Change -0.64% 81.79% -15.27%
INVESTING ACTIVITIES
Capital Expenditures $4.671M -$8.820M -$7.751M
YoY Change -118.23% 13.79% 92.81%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$4.671M -$8.820M -$7.751M
YoY Change -81.77% 13.79% 92.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.229M -4.625M 37.96M
YoY Change -83.48% -112.18% 89.14%
NET CHANGE
Cash From Operating Activities -22.30M -23.53M -12.95M
Cash From Investing Activities -4.671M -8.820M -7.751M
Cash From Financing Activities 7.229M -4.625M 37.96M
Net Change In Cash -19.74M -36.98M 17.26M
YoY Change 359.14% -314.2% 2142.08%
FREE CASH FLOW
Cash From Operating Activities -$22.30M -$23.53M -$12.95M
Capital Expenditures $4.671M -$8.820M -$7.751M
Free Cash Flow -$26.97M -$14.71M -$5.195M
YoY Change -948.98% 183.25% -53.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
29591000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
18535000 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
usd
CY2021Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
usd
CY2022Q3 tnxp Issuance Of Commitment Shares Under Purchase Agreement2
IssuanceOfCommitmentSharesUnderPurchaseAgreement2
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001430306
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q2 tnxp Stock Issued During Period Value New Issues20
StockIssuedDuringPeriodValueNewIssues20
usd
tnxp Common Stock Issued To Acquire Research And Development
CommonStockIssuedToAcquireResearchAndDevelopment
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
usd
us-gaap Payments For Repurchase Of Redeemable Convertible Preferred Stock
PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock
usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-438358000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
139978000 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
840000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
886000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
382000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
504000 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36019
dei Entity Registrant Name
EntityRegistrantName
TONIX PHARMACEUTICALS HOLDING CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1434750
dei Entity Address Address Line1
EntityAddressAddressLine1
26 Main Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 101
dei Entity Address City Or Town
EntityAddressCityOrTown
Chatham
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07928
dei City Area Code
CityAreaCode
(862)
dei Local Phone Number
LocalPhoneNumber
799-9155
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
TNXP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
379000 usd
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
489000 usd
dei Entity Small Business
EntitySmallBusiness
true
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13340000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21716000 usd
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
382000 usd
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
57536293 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
139978000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
467000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
13722000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13282000 usd
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
8280000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
178660000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11161000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10389000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
151139000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
189049000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
90307000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50558000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
840000 usd
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
7945000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
504000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
914000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
360000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13082000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57202000 usd
CY2022Q3 us-gaap Assets
Assets
242646000 usd
CY2021Q4 us-gaap Assets
Assets
240900000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4556000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
22183000 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q3 tnxp Preferred Stock Shares Designated
PreferredStockSharesDesignated
0 shares
CY2021Q4 tnxp Preferred Stock Shares Designated
PreferredStockSharesDesignated
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53321511 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53321511 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15638274 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15638274 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
53000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
16000 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
667389000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
578613000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-438358000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-359820000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-160000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-92000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
228924000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
218717000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
242646000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
240900000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22201000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46542000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7390000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5453000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22161000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
825000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
99000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-28981000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-18528000 usd
us-gaap Net Income Loss
NetIncomeLoss
-78538000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16291000 usd
us-gaap Costs And Expenses
CostsAndExpenses
79363000 usd
us-gaap Costs And Expenses
CostsAndExpenses
62833000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29591000 usd
CY2022Q1 tnxp Stock Issued During Period Value New Issues10
StockIssuedDuringPeriodValueNewIssues10
8488000 usd
CY2022Q1 tnxp Issuance Of Commitment Shares Under Purchase Agreement
IssuanceOfCommitmentSharesUnderPurchaseAgreement
4535000 usd
us-gaap Net Income Loss
NetIncomeLoss
-62734000 usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
4255000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
40000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18535000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-79363000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-62833000 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
610000 usd
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
7000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28981000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18528000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-82793000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-62734000 usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.60
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.02
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41944289 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41944289 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11581367 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11581367 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27066489 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27066489 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10429028 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10429028 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-28981000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-18528000 usd
us-gaap Net Income Loss
NetIncomeLoss
-78538000 usd
us-gaap Net Income Loss
NetIncomeLoss
-62734000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-17000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-10000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-68000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-19000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28998000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18538000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78606000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-62753000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
218717000 usd
CY2021Q1 tnxp Stock Issued During Period Value New Issues15
StockIssuedDuringPeriodValueNewIssues15
64997000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
2620000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-26000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-26417000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
207957000 usd
CY2022Q2 tnxp Stock Issued During Period Value New Issues11
StockIssuedDuringPeriodValueNewIssues11
42968000 usd
CY2022Q2 tnxp Issuance Of Commitment Shares Under Purchase Agreement
IssuanceOfCommitmentSharesUnderPurchaseAgreement
1964000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
4255000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
2813000 usd
CY2021Q1 tnxp Stock Issued During Period Value New Issues1
StockIssuedDuringPeriodValueNewIssues1
2000 usd
CY2021Q1 tnxp Stock Issued During Period Value New Issues14
StockIssuedDuringPeriodValueNewIssues14
36904000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-25000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-23140000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1147000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-75752000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
228282000 usd
CY2022Q3 tnxp Stock Issued During Period Value New Issues4
StockIssuedDuringPeriodValueNewIssues4
24692000 usd
CY2022Q3 tnxp Issuance Of Commitment Shares Under Purchase Agreement
IssuanceOfCommitmentSharesUnderPurchaseAgreement
2183000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
2765000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-17000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-28981000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
228924000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
87648000 usd
CY2021Q1 tnxp Stock Issued During Period Value New Issues19
StockIssuedDuringPeriodValueNewIssues19
6779000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
28000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
1212000 usd
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-20653000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
176916000 usd
CY2021Q2 tnxp Stock Issued During Period Value New Issues2
StockIssuedDuringPeriodValueNewIssues2
18702000 usd
CY2021Q2 tnxp Issuance Of Commitment Shares Under Purchase Agreement
IssuanceOfCommitmentSharesUnderPurchaseAgreement
3347000 usd
CY2021Q2 tnxp Stock Issued During Period Value New Issues21
StockIssuedDuringPeriodValueNewIssues21
3000000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
2089000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-8000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-23553000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
180493000 usd
CY2021Q3 tnxp Stock Issued During Period Value New Issues3
StockIssuedDuringPeriodValueNewIssues3
11728000 usd
CY2021Q3 tnxp Issuance Of Commitment Shares Under Purchase Agreement
IssuanceOfCommitmentSharesUnderPurchaseAgreement
26165000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
68000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
2302000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-10000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-18528000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
202218000 usd
us-gaap Net Income Loss
NetIncomeLoss
-78538000 usd
us-gaap Net Income Loss
NetIncomeLoss
-62734000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
417000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
23000 usd
tnxp Common Stock Issued To Acquire Research And Development
CommonStockIssuedToAcquireResearchAndDevelopment
3000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8198000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5603000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
753000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1217000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-4079000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
3370000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
5000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-10000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1002000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53112000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
43476000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9685000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
168622000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
80615000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-43476000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9685000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
40000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
96000 usd
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
27245000 usd
us-gaap Payments For Repurchase Of Redeemable Convertible Preferred Stock
PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock
31500000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
84830000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
168720000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-69000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-21000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38682000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
105902000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
178900000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77308000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
140218000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
183210000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3310000 usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
4255000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_809_eus-gaap--NatureOfOperations_zujKStDOGr32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 – <span id="xdx_824_z36rQIVJuv6h">BUSINESS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tonix Pharmaceuticals Holding Corp., through its wholly owned subsidiary Tonix Pharmaceuticals, Inc. (“Tonix Sub”), is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. The therapeutics include both small molecules and biologics. All drug product and vaccine candidates are still in development and none are approved or marketed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The condensed consolidated financial statements include the accounts of Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiaries, Tonix Sub, Krele LLC, Tonix Pharmaceuticals (Canada), Inc., Tonix Medicines, Inc., Jenner LLC, Tonix R&amp;D Center LLC, Tonix Pharma Holdings Limited and Tonix Pharma Limited (collectively hereafter referred to as the “Company” or “Tonix”). All intercompany balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Going Concern</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company has suffered recurring losses from operations and negative cash flows from operating activities. At September 30, 2022, the Company had working capital of approximately $<span id="xdx_90F_ecustom--WorkingCapital_iI_pn3d_dm_c20220930_zoXfAnZZ3B27" title="Working capital">137.8 million</span>. At September 30, 2022, the Company had an accumulated deficit of approximately $<span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn3n3_dxL_c20220930_zKianL0YtQs3" title="Accumulated deficit::XDX::-438358"><span style="-sec-ix-hidden: xdx2ixbrl0678">438.4 million</span></span>. The Company held cash and cash equivalents of approximately $<span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dxL_c20220930_z392n5rkTho" title="Cash and cash equivalents::XDX::139978"><span style="-sec-ix-hidden: xdx2ixbrl0680">140.0 million</span></span> as of September 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company believes that its cash resources at September 30, 2022, and the gross proceeds of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n6_c20221001__20221107__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQh1pET1KUSg" title="Proceeds from equity offerings">2.1</span> million, that it raised from equity offerings subsequent to the end of the third quarter of 2022 (See Note 19), will allow the Company to meet its operating and capital expenditure requirements into the third quarter of 2023, but not beyond.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company continues to face significant challenges and uncertainties and, as a result, its available capital resources may be consumed more rapidly than currently expected due to changes it may make in its research and development spending plans. The Company believes that it has the ability to obtain additional funding through public and private financing and collaborative arrangements with strategic partners to increase the funds available to fund operations. However, the Company may not be able to raise capital on terms acceptable to the Company. Without additional funds, it may be forced to delay, scale back or eliminate some of its research and development activities, or other operations and potentially delay product development in an effort to provide sufficient funds to continue operations. If any of these events occurs, the Company’s ability to achieve its development and commercialization goals would be adversely affected. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
CY2022Q3 tnxp Working Capital
WorkingCapital
137800000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zVToNH7T1PN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Risks and uncertainties</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company’s primary efforts are devoted to conducting research and development of innovative pharmaceutical and biological products to address public health challenges. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. Further, the Company does not have any commercial products available for sale and has not generated revenues, and there is no assurance that if its products are approved for sale, that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable. Moreover, the extent to which COVID-19 impacts the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zgGA7scAAGfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Use of estimates</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in accordance with Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the assumptions used in the fair value of stock-based compensation and other equity instruments, and the percent of completion of research and development contracts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
CY2022Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
121200000 usd
CY2021Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
120400000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
240000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
240000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
139978000 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
182970000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
240000 usd
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
240000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
140218000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
183210000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
805762 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
78.02
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
252000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
417000 usd
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
10000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
23000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M29D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1695608 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
46090 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2475250 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
825898 shares
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
91124000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
50958000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
817000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
400000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
90307000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50558000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
267.12
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2455280 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.92
tnxp Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3
P8Y11M12D
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
800000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q2 tnxp Minimum Bid Requirement Per Share
MinimumBidRequirementPerShare
1.00
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
135000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
438000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
532615 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
74.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y9M10D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.25
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
21.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
33.78
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0167 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0305 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0079 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0163 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.2032 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.3322 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.2437 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.3773 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
19970 shares
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
163000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
159000 usd
CY2022Q3 tnxp Lessee Operating Lease Liability Payments Due After Year Three
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
11000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
906000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
20000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
886000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000 usd
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
500000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
447000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
479000 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M29D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M14D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0226 pure
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0134 pure
CY2022Q3 us-gaap Other Commitment
OtherCommitment
61400000 usd

Files In Submission

Name View Source Status
tnxp-20220930_lab.xml Edgar Link unprocessable
tnxp-20220930_def.xml Edgar Link unprocessable
0001387131-22-011157-index-headers.html Edgar Link pending
0001387131-22-011157-index.html Edgar Link pending
0001387131-22-011157.txt Edgar Link pending
0001387131-22-011157-xbrl.zip Edgar Link pending
ex31-01.htm Edgar Link pending
ex31-02.htm Edgar Link pending
ex32-01.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
tnxp-20220930_pre.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tnxp-10q_093022.htm Edgar Link pending
tnxp-20220930.xsd Edgar Link pending
tnxp-20220930_cal.xml Edgar Link unprocessable
tnxp-10q_093022_htm.xml Edgar Link completed